Clinical importance of identifying immunoglobulin E-mediated disease in patients with Asthma

Clinical Cornerstone

Volumn 9, Issue 3, 2009, Pages 20-29

  Casale, Thomas B ^a   Martin, Richard J ^b  

^a CREIGHTON UNIVERSITY   (United States)

^b National Jewish Center for Immunology Denver   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; OMALIZUMAB; STEROID;

ADD ON THERAPY; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ALLERGY; ALLERGY TEST; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ARTICLE; ASTHMA; ATOPY; BEHAVIOR THERAPY; BRONCHUS HYPERREACTIVITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; ECZEMA; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INCIDENCE; LABORATORY TEST; MAST CELL; MEDICAL SPECIALIST; OBSERVATIONAL STUDY; PATIENT EDUCATION; PRACTICE GUIDELINE; PREVALENCE; PREVENTIVE HEALTH SERVICE; RESPIRATORY TRACT INFLAMMATION; RHINOCONJUNCTIVITIS; SENSITIVITY AND SPECIFICITY; SENSITIZATION; SKIN TEST; SYMPTOM; WHEEZING;

ASTHMA; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; PRACTICE GUIDELINES AS TOPIC; RADIOALLERGOSORBENT TEST; RISK FACTORS; SKIN TESTS;

EID: 70349225605     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(09)80009-4     Document Type: Article

References (27)

1. Bousquet J., Wahn U., Meltzer E.O., et al. Omalizumab: An anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases. Eur Resp Rev. 17 (2008) 1-9
2. Johansson S.G., Bieber T., Dahl R., et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 113 (2004) 832-836
3. Fromer L.M. Clinical rationale for obtaining a precise diagnosis. J Fam Pract Suppl (2004) S4-S14
4. Høst A., and Halken S. The role of allergy in childhood asthma. Allergy 55 (2000) 600-608
5. Akinbami L. Asthma prevalence, health care use and mortality. United States (2003). http://www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma03-05/asth-ma03-05.htm Accessed February 6, 2009
6. National Institutes of Health. Data fact sheet. Asthma statistics. http://www.nhlbi.nih.gov/health/prof/lung/asthma/asthstat.pdf Accessed February 11, 2009
7. Milgrom H. Understanding allergic asthma. AAAAI News Release (June 18, 2003)
8. National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (2007), National Institutes of Health, Bethesda, Md August 2007. NIH publication 07-4051
9. Halpern M.T., Schmier J.K., Richner R., et al. Allergic rhinitis: A potential cause of increased asthma medication use, costs, and morbidity. J Asthma 41 (2004) 117-126
10. National Center for Health Statistics. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments. United States (1999), Vital and Health Statistics 2000, Series 13, No. 157. DHHS publication. 2004-1728
11. Burrows B., Martinez F.D., Halonen M., et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 320 (1989) 271-277
12. Oettgen H.C., and Geha R.S. IgE regulation and roles in asthma pathogenesis [published correction appears in J Allergy Clin Immunol. 2001;107:591]. J Allergy Clin Immunol 107 (2001) 429-440
13. Schmidt D., Watson N., Ruehlmann E., et al. Serum immunoglobulin E levels predict human airway reactivity in vitro. Clin Exp Allergy 30 (2000) 233-241
14. Martinez F.D. Present and future treatment of asthma in infants and young children. J Allergy Clin Immunol 104 4 Pt 2 (1999) 169-174
15. Platts-Mills T.A. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 164 8 Pt 2 (2001) S1-S5
16. Wittig H.J., Belloit J., De Fillippi I., and Royal G. Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. J Allergy Clin Immunol 66 (1980) 305-313
17. Arbes Jr. S.J., Cohn R.D., Yin M., et al. House dust mite allergen in US beds: Results from the First National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol 111 (2003) 408-414
18. Asthma and Allergy Foundation of America. Pet allergies. http:www.aafa.org Accessed February 11, 2009
19. Platts-Mills T., Leung D.Y., and Schatz M. The role of allergens in asthma. Am Fam Physician 76 (2007) 675-680
20. Vinuya R.Z. Upper airway disorders and asthma: A syndrome of airway inflammation. Ann Allergy Asthma Immunol 88 Suppl 4 (2002) 8-15
21. American Academy of Allergy, Asthma, and Immunology. Allergen immunotherapy: A practice parameter. Ann Allergy Asthma Immunol 90 Suppl 1 (2003) S1-S40
22. Bachert C., and van Cauwenberge P. The WHO ARIA (allergic rhinitis and its impact on asthma) initiative. Chem Immunol Allergy 82 (2003) 119-126
23. Frew A.J. Immunotherapy of allergic disease. J Allergy Clin Immunol 111 Suppl 2 (2003) S712-S719
24. Buhl R., Solèr M., Matz J., et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 20 (2002) 73-78
25. Busse W.W. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med. 164 8 Pt 2 (2001) S12-S17
26. Solèr M., Matz J., Townley R., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics [published correction appears in Eur Respir J. 2001;18:739-740]. Eur Respir J. 18 (2001) 254-261
27. Bousquet J., Cabrera P., Berkman N., et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60 (2005) 302-308